Literature DB >> 14978397

[Reversible cardiac valve abnormalities with pergolide treatment].

V Calomne1, M J-M Dupuis, T Muller, F Kempinere.   

Abstract

We report the case of a parkinsonian patient treated by pergolide who developed aortic and mitral regurgitations and pulmonary hypertension. When she stopped the medication, the cardiac symptoms disappeared. Retroperitoneal and pleural fibrosis have been described with pergolide but never valvulopathy until 3 cases reported in December 2002.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978397     DOI: 10.1016/s0035-3787(04)70850-4

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Acute pergolide exposure stiffens engineered valve interstitial cell tissues and reduces contractility in vitro.

Authors:  Andrew K Capulli; Luke A MacQueen; Blakely B O'Connor; Stephanie Dauth; Kevin Kit Parker
Journal:  Cardiovasc Pathol       Date:  2016-04-25       Impact factor: 2.185

Review 2.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Authors:  Malcolm Steiger; W Jost; F Grandas; G Van Camp
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

Review 3.  Restless legs syndrome: pathophysiology, diagnosis and treatment.

Authors:  Pankaj Satija; William G Ondo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.